• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 和肿瘤浸润的 CD8 淋巴细胞与儿科和青少年垂体腺瘤的临床特征相关。

PD-L1 and tumor-infiltrating CD8 lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas.

机构信息

Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China.

Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China.

出版信息

Front Endocrinol (Lausanne). 2023 Jun 22;14:1151714. doi: 10.3389/fendo.2023.1151714. eCollection 2023.

DOI:10.3389/fendo.2023.1151714
PMID:37424874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10323746/
Abstract

OBJECTIVE

To investigate the levels of tumor-infiltrating CD8 lymphocytes (CD8 TILs) and the expression of programmed cell death receptor ligand 1 (PD-L1) in the tumor microenvironment (TME) of pediatric and adolescent pituitary adenomas (PAPAs) and analyze the correlation between their levels and the clinical characteristics.

METHODS

A series of 43 PAPAs cases were enrolled over a period of 5 years. To compare the TME of PAPAs and adult PAs, 43 PAPAs cases were matched with 60 adult PAs cases (30 cases were between 20 and 40 years old, and 30 cases were older than 40 years) for main clinical characteristics. The expression of immune markers in PAPAs was detected by immunohistochemistry, and their correlation with the clinical outcomes was analyzed using statistical methods.

RESULTS

In the PAPAs group, CD8 TILs level was significantly lower (3.4 (5.7) vs. 6.1 (8.5), p = 0.001), and PD-L1 expression (0.040 (0.022) vs. 0.024 (0.024), p < 0.0001) was significantly higher as compared with the older group. The level of CD8 TILs was negatively correlated with the expression of PD-L1 (r = -0.312, p = 0.042). Moreover, CD8 TILs and PD-L1 levels were associated with Hardy (CD8, p = 0.014; PD-L1, p = 0.018) and Knosp (CD8, p = 0.02; PD-L1, p = 0.017) classification. CD8 TILs level was associated with high-risk adenomas (p = 0.015), and it was associated with the recurrence of PAPAs (HR = 0.047, 95% CI 0.003-0.632, p = 0.021).

CONCLUSION

Compared with the TME in adult PAs, the TME in PAPAs was found to express a significantly altered level of CD8 TILs and PD-L1. In PAPAs, CD8 TILs and PD-L1 levels were associated with clinical characteristics.

摘要

目的

研究儿童和青少年垂体腺瘤(PAPA)肿瘤微环境(TME)中肿瘤浸润性 CD8 淋巴细胞(CD8 TILs)水平和程序性死亡受体配体 1(PD-L1)的表达,并分析其水平与临床特征的相关性。

方法

本研究纳入了 5 年内的 43 例 PAPA 病例。为了比较 PAPA 和成人 PAs 的 TME,将 43 例 PAPA 病例与 60 例成人 PAs 病例(20-40 岁 30 例,>40 岁 30 例)进行主要临床特征匹配。采用免疫组织化学法检测 PAPA 中免疫标志物的表达,并采用统计学方法分析其与临床结局的相关性。

结果

在 PAPA 组中,CD8 TILs 水平明显较低(3.4(5.7)vs. 6.1(8.5),p = 0.001),PD-L1 表达(0.040(0.022)vs. 0.024(0.024),p < 0.0001)明显较高。CD8 TILs 水平与 PD-L1 表达呈负相关(r = -0.312,p = 0.042)。此外,CD8 TILs 和 PD-L1 水平与 Hardy(CD8,p = 0.014;PD-L1,p = 0.018)和 Knosp(CD8,p = 0.02;PD-L1,p = 0.017)分级相关。CD8 TILs 水平与高危腺瘤有关(p = 0.015),与 PAPA 复发有关(HR = 0.047,95%CI 0.003-0.632,p = 0.021)。

结论

与成人 PAs 的 TME 相比,PAPA 的 TME 中 CD8 TILs 和 PD-L1 的表达水平明显改变。在 PAPA 中,CD8 TILs 和 PD-L1 水平与临床特征相关。

相似文献

1
PD-L1 and tumor-infiltrating CD8 lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas.PD-L1 和肿瘤浸润的 CD8 淋巴细胞与儿科和青少年垂体腺瘤的临床特征相关。
Front Endocrinol (Lausanne). 2023 Jun 22;14:1151714. doi: 10.3389/fendo.2023.1151714. eCollection 2023.
2
The expression profile of PD-L1 and CD8 lymphocyte in pituitary adenomas indicating for immunotherapy.垂体腺瘤中 PD-L1 和 CD8 淋巴细胞的表达谱提示免疫治疗。
J Neurooncol. 2018 Aug;139(1):89-95. doi: 10.1007/s11060-018-2844-2. Epub 2018 Apr 21.
3
Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.程序性死亡配体 1 表达和肿瘤浸润淋巴细胞在轴性骨肉瘤中的预后意义。
World Neurosurg. 2019 Sep;129:e240-e254. doi: 10.1016/j.wneu.2019.05.121. Epub 2019 May 22.
4
Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.唾液腺癌中 CD8 阳性肿瘤浸润淋巴细胞和 PD-L1 表达的预后影响。
Oral Oncol. 2020 Dec;111:104931. doi: 10.1016/j.oraloncology.2020.104931. Epub 2020 Jul 28.
5
Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).程序性死亡配体-1和CD8肿瘤浸润淋巴细胞(TILs)作为高级别浆液性卵巢癌(HGSC)的预后预测指标
J Egypt Natl Canc Inst. 2021 Jul 9;33(1):16. doi: 10.1186/s43046-021-00073-5.
6
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.新辅助放化疗前后直肠癌细胞程序性死亡配体 1 表达和 CD8+TILs 与患者预后的相关性。
J Cancer Res Clin Oncol. 2019 Apr;145(4):1043-1053. doi: 10.1007/s00432-019-02874-7. Epub 2019 Mar 14.
7
Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.基于肿瘤免疫微环境和外周血 T 细胞表型鉴定和验证用于胃癌预后的新型生存预测模型。
J Transl Med. 2023 Feb 3;21(1):73. doi: 10.1186/s12967-023-03922-0.
8
Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer.肿瘤 PD-L1 表达联合 CD8 肿瘤浸润淋巴细胞对高级别浆液性卵巢癌的预后价值。
Int Immunopharmacol. 2017 Nov;52:7-14. doi: 10.1016/j.intimp.2017.08.017. Epub 2017 Aug 31.
9
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.免疫治疗在难治性垂体腺瘤和垂体癌中的进展。
Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020.
10
Programmed Death Ligand 1 (PD-L1) Expression and CD8 + Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy.程序性死亡配体 1(PD-L1)表达和基于 CD8+肿瘤浸润淋巴细胞的肿瘤免疫微环境分类在妇科癌肉瘤中的预后影响及治疗意义。
Int J Gynecol Pathol. 2023 Jul 1;42(4):364-375. doi: 10.1097/PGP.0000000000000890. Epub 2022 May 16.

引用本文的文献

1
New approaches to targeted drug therapy of intracranial tumors.颅内肿瘤靶向药物治疗的新方法。
Cell Death Discov. 2025 Mar 20;11(1):111. doi: 10.1038/s41420-025-02358-3.
2
New insights on anti-tumor immunity of CD8 T cells: cancer stem cells, tumor immune microenvironment and immunotherapy.CD8 T细胞抗肿瘤免疫的新见解:癌症干细胞、肿瘤免疫微环境与免疫治疗
J Transl Med. 2025 Mar 17;23(1):341. doi: 10.1186/s12967-025-06291-y.
3
PD-L1 expression in PitNETs: Correlations with the 2022 WHO classification.垂体神经内分泌肿瘤中PD-L1的表达:与2022年世界卫生组织分类的相关性

本文引用的文献

1
Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.真实世界中免疫治疗对垂体瘤的疗效和预测因素:一项队列研究。
Eur J Endocrinol. 2022 Oct 17;187(5):685-696. doi: 10.1530/EJE-22-0647. Print 2022 Nov 1.
2
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.错配修复缺陷型侵袭性垂体腺瘤患者对免疫检查点抑制剂治疗的完全缓解:病例报告。
Neurosurgery. 2022 Aug 1;91(2):e51-e56. doi: 10.1227/neu.0000000000002024. Epub 2022 May 13.
3
High-risk pituitary adenomas and strategies for predicting response to treatment.
Brain Spine. 2024 Dec 24;5:104171. doi: 10.1016/j.bas.2024.104171. eCollection 2025.
4
Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.肿瘤微环境在垂体神经内分泌肿瘤中的作用:分类、诊断和治疗的新方法
Cancers (Basel). 2023 Nov 6;15(21):5301. doi: 10.3390/cancers15215301.
5
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas.垂体神经内分泌肿瘤/垂体腺瘤中的程序性死亡受体配体1(PD-L1)表达
Cancers (Basel). 2023 Sep 8;15(18):4471. doi: 10.3390/cancers15184471.
高危垂体腺瘤及治疗反应预测策略。
Hormones (Athens). 2022 Mar;21(1):1-14. doi: 10.1007/s42000-021-00333-y. Epub 2022 Jan 21.
4
Pediatric pituitary adenomas are more aggressive, more likely to be hormone producing and are more difficult to cure than adult pituitary adenomas: case series and systematic literature review.小儿垂体腺瘤比成人垂体腺瘤更具侵袭性,更有可能产生激素,且更难治愈:病例系列和系统文献回顾。
Childs Nerv Syst. 2022 Apr;38(4):729-738. doi: 10.1007/s00381-022-05445-3. Epub 2022 Jan 19.
5
Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy.垂体癌是否应采用类神经内分泌肿瘤(NET)的方法进行治疗?一例转移性恶性泌乳素瘤经包括免疫疗法在内的多模式治疗完全缓解的病例。
Clin Endocrinol (Oxf). 2023 Apr;98(4):633-637. doi: 10.1111/cen.14645. Epub 2021 Nov 29.
6
Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma.检查点抑制剂与肽受体放射性核素疗法在垂体癌治疗中的协同作用
J Endocr Soc. 2021 Aug 7;5(10):bvab133. doi: 10.1210/jendso/bvab133. eCollection 2021 Oct 1.
7
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.实体瘤中肿瘤浸润淋巴细胞治疗的观点。
BMC Med. 2021 Jun 11;19(1):140. doi: 10.1186/s12916-021-02006-4.
8
Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.垂体腺瘤免疫研究进展及免疫治疗前景
World J Surg Oncol. 2021 Jun 5;19(1):162. doi: 10.1186/s12957-021-02272-9.
9
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.帕博利珠单抗治疗垂体癌患者的疗效:来自 II 期研究的 4 例报告。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001532.
10
Tumor microenvironment as a therapeutic target in cancer.肿瘤微环境作为癌症治疗靶点。
Pharmacol Ther. 2021 May;221:107753. doi: 10.1016/j.pharmthera.2020.107753. Epub 2020 Nov 28.